Roche to Buy Biopharmaceutical Firm 89bio in $3.5 Billion Deal

Roche Holding AG said it will acquire biopharmaceutical company 89bio, Inc. in a deal valued at $3.5 billion, bolstering the Swiss pharmaceutical giant’s pipeline of cardiovascular, renal, and metabolic disease treatments....

Redirecting to full article...